Daraxonrasib and chemotherapy halted pancreatic cancer growth in 90% of 61 patients
In a phase 1/2 trial of 61 people with advanced pancreatic cancer, daraxonrasib combined with chemotherapy stopped tumours growing in 90.2%; tumours shrank or disappeared in 60.7%, and scans showed no detectable tumours in 8.2%. Researchers presented the findings in Barcelona, but the study had no chemotherapy-only comparison group, and longer trials are needed to establish whether the combination improves survival.
Bottom line — The ongoing phase 3 RASolute 303 trial will compare the combination with chemotherapy alone.
Go deeper 5
-
The trial combined a daily daraxonrasib pill with gemcitabine and nab-paclitaxel chemotherapy, according to MedicalDaily.
-
After a median follow-up of 18.3 months, 76.6% of participants were alive at one year, MedicalDaily reported.
-
MedicalDaily reported that the median time before the cancer worsened was 12.8 months; comparisons with earlier chemotherapy studies are not direct.
-
Wungki Park of Memorial Sloan Kettering called the results “the closest to cure”; researchers caution that no visible tumour on a scan does not establish a cure, the BBC reported.
-
Daraxonrasib targets RAS signalling, which drives tumour growth in most pancreatic cancers, according to the BBC.